SEC Filings
REGENXBIO Loses Royalty Revenue As Patent Expirations Cut Zolgensma Payments By $21.2 Million
A $38.0 million patent-settlement gain helped narrow the quarterly loss as spending on Duchenne trials increased.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
A $38.0 million patent-settlement gain helped narrow the quarterly loss as spending on Duchenne trials increased.
SEC Filings
The disclosed portfolio reached $348.3 billion, with Nvidia the largest holding and a $5.2 billion ExxonMobil Holdings entry.
Earnings
Management says dealmaking will continue, while a pending Eagle Ford sale is expected to fund more share buybacks.
Deals
The independent committee favors its restaurant turnaround plan, while new takeover rules can dilute buyers who cross the ownership threshold.
Earnings
Management says current deal prospects fit its funding capacity, while the board will consider dividend increases early in the New Year.
Markets
The fiber-optic supplier forecasts higher fourth-quarter sales, but construction and power-access delays will slow its U.S. expansion.
Earnings
The apartment owner canceled purchases and paused Denver and Nashville developments while trimming its property-growth outlook.
Earnings
Third-quarter sales grew 1.5%, while reported and adjusted profits moved in opposite directions.
Markets
The drug developer’s third-quarter loss widened to $20.3 million as research costs rose, with trial results expected in 2027.
Earnings
With its same-property portfolio 97% leased, Regency is choosing replacement tenants and seeking fewer renewal options.
Earnings
The company authorized up to an additional $12 billion in buybacks and expects its full-year adjusted earnings margin to reach about 36%.
Earnings
The biotech expects Alzheimer’s imaging results in the fourth quarter and first gene-therapy dosing in the coming months, pending enrollment.